openPR Logo
Press release

Idiopathic Pulmonary Fibrosis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics

04-15-2024 06:14 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Idiopathic Pulmonary Fibrosis Market to Exhibit Rapid Growth

The Idiopathic Pulmonary Fibrosis Market size was valued approximately USD 3,327 million in 2022 and the report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the 7MM.
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Idiopathic Pulmonary Fibrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Idiopathic Pulmonary Fibrosis Market Forecast [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Idiopathic Pulmonary Fibrosis Market Report:

* The Idiopathic Pulmonary Fibrosis market size was valued approximately USD 3,327 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
* There are numerous emerging therapies being explored for the treatment of idiopathic pulmonary fibrosis (IPF), including the promising drug Tyvaso (treprostinil), BI 1015550, and various others.
* The largest market share for Idiopathic Pulmonary Fibrosis is attributed to the United States, reaching approximately USD 2,321 million in 2021. Projections indicate a substantial Compound Annual Growth Rate (CAGR) for the study duration (2019-2032), with expectations of further increase by 2032.
* In August 2023, Pliant Therapeutics commenced the Phase IIb BEACON-IPF clinical trial, investigating bexotegrast (PLN-74809) as a potential treatment for idiopathic pulmonary fibrosis (IPF). This study, conducted in a double-blind manner and spanning multiple countries, will assess the efficacy of bexotegrast at doses of either 160mg or 320mg in IPF patients through a dose-ranging approach.
* The collective market size for Idiopathic Pulmonary Fibrosis in the EU4 and the UK amounted to USD 693 million in 2021, and there are expectations of growth throughout the study period.
* The overall number of diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in the 7MM reached 194,878 cases in 2021, and there is an anticipated increase at a notable Compound Annual Growth Rate (CAGR) over the study period (2019-2032).
* In 2021, the United States recorded the highest number of diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) within the 7MM, totaling 94,736 cases. This figure is anticipated to experience a significant increase in the near future, attributed to advancements in diagnostic testing and a growing population.
* Key Idiopathic Pulmonary Fibrosis Companies: CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, AstraZeneca, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd, Ark Biosciences, Ocean Biomedical, and others
* Key Idiopathic Pulmonary Fibrosis Therapies: Tyvaso, BI 1015550, PLN-74809, HZN-825, Garadacimab, MN-001, LYT-100, C21, Pamrevlumab, Tipelukast, PLN-74809, TTI-101, Taladegib, Olitigaltin, and others
* The Idiopathic Pulmonary Fibrosis epidemiology based on gender analyzed that the males predominantly has the higher number of diagnosed prevalent cases than females. In 2021, 121,389 males and 73,488 females were affected by Idiopathic Pulmonary Fibrosis in the 7MM.
* The Idiopathic Pulmonary Fibrosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Idiopathic Pulmonary Fibrosis pipeline products will significantly revolutionize the Idiopathic Pulmonary Fibrosis market dynamics.

Idiopathic Pulmonary Fibrosis Overview

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive lung disease characterized by the thickening and scarring of the lung tissue, a process known as fibrosis. The exact cause of IPF is unknown, hence the term "idiopathic," but it is believed to involve a combination of genetic predisposition and environmental factors such as cigarette smoking, occupational exposure to certain pollutants, and viral infections.

Get a Free sample for the Idiopathic Pulmonary Fibrosis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-market [https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Idiopathic Pulmonary Fibrosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Idiopathic Pulmonary Fibrosis Epidemiology Segmentation:

The Idiopathic Pulmonary Fibrosis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

* Total Prevalence of Idiopathic Pulmonary Fibrosis
* Prevalent Cases of Idiopathic Pulmonary Fibrosis by severity
* Gender-specific Prevalence of Idiopathic Pulmonary Fibrosis
* Diagnosed Cases of Episodic and Chronic Idiopathic Pulmonary Fibrosis

Download the report to understand which factors are driving Idiopathic Pulmonary Fibrosis epidemiology trends @ Idiopathic Pulmonary Fibrosis Epidemiology Forecast [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Idiopathic Pulmonary Fibrosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Idiopathic Pulmonary Fibrosis market or expected to get launched during the study period. The analysis covers Idiopathic Pulmonary Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Idiopathic Pulmonary Fibrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Idiopathic Pulmonary Fibrosis Therapies and Key Companies

* Tyvaso: United Therapeutics
* BI 1015550: Boehringer Ingelheim
* PLN-74809: Pliant Therapeutics
* HZN-825: Horizon Therapeutics
* Garadacimab: CSL Behring
* MN-001: MediciNova
* LYT-100: PureTech
* C21: Vicore Pharma AB
* Pamrevlumab: FibroGen
* Tipelukast: MediciNova
* PLN-74809: Pliant Therapeutics
* TTI-101: Tvardi Therapeutics
* Taladegib: Endeavor BioMedicines
* Olitigaltin: Galecto Inc

Discover more about therapies set to grab major Idiopathic Pulmonary Fibrosis market share @ Idiopathic Pulmonary Fibrosis Treatment Landscape [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Idiopathic Pulmonary Fibrosis Market Strengths

* Growing research activities to treat and detect pulmonary fibrosis and how it develops will play an important role in disease diagnosis and drug development. Any innovation in this field will help in strengthening the market.

Idiopathic Pulmonary Fibrosis Market Opportunities

* Severe segment of Idiopathic Pulmonary Fibrosis remains opportunistic as very few therapies are targeting these patients.

Scope of the Idiopathic Pulmonary Fibrosis Market Report

* Study Period: 2019-2032
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Idiopathic Pulmonary Fibrosis Companies: CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, AstraZeneca, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd, Ark Biosciences, Ocean Biomedical, and others
* Key Idiopathic Pulmonary Fibrosis Therapies: Tyvaso, BI 1015550, PLN-74809, HZN-825, Garadacimab, MN-001, LYT-100, C21, Pamrevlumab, Tipelukast, PLN-74809, TTI-101, Taladegib, Olitigaltin, and others
* Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Idiopathic Pulmonary Fibrosis current marketed and Idiopathic Pulmonary Fibrosis emerging therapies
* Idiopathic Pulmonary Fibrosis Market Dynamics: Idiopathic Pulmonary Fibrosis market drivers and Idiopathic Pulmonary Fibrosis market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Idiopathic Pulmonary Fibrosis Unmet Needs, KOL's views, Analyst's views, Idiopathic Pulmonary Fibrosis Market Access and Reimbursement

To know more about Idiopathic Pulmonary Fibrosis companies working in the treatment market, visit @ Idiopathic Pulmonary Fibrosis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Idiopathic Pulmonary Fibrosis Market Report Introduction

2. Executive Summary for Idiopathic Pulmonary Fibrosis

3. SWOT analysis of Idiopathic Pulmonary Fibrosis

4. Idiopathic Pulmonary Fibrosis Patient Share (%) Overview at a Glance

5. Idiopathic Pulmonary Fibrosis Market Overview at a Glance

6. Idiopathic Pulmonary Fibrosis Disease Background and Overview

7. Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Idiopathic Pulmonary Fibrosis

9. Idiopathic Pulmonary Fibrosis Current Treatment and Medical Practices

10. Idiopathic Pulmonary Fibrosis Unmet Needs

11. Idiopathic Pulmonary Fibrosis Emerging Therapies

12. Idiopathic Pulmonary Fibrosis Market Outlook

13. Country-Wise Idiopathic Pulmonary Fibrosis Market Analysis (2019-2032)

14. Idiopathic Pulmonary Fibrosis Market Access and Reimbursement of Therapies

15. Idiopathic Pulmonary Fibrosis Market Drivers

16. Idiopathic Pulmonary Fibrosis Market Barriers

17. Idiopathic Pulmonary Fibrosis Appendix

18. Idiopathic Pulmonary Fibrosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=idiopathic-pulmonary-fibrosis-market-to-exhibit-rapid-growth-rate-during-the-forecast-period-20232032-investigates-delveinsight-united-therapeutics-boehringer-ingelheim-pliant-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Idiopathic Pulmonary Fibrosis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics here

News-ID: 3464565 • Views:

More Releases from ABNewswire

Holiday Skin Stress? KREMOLOGIE Trademark Offers Professional Solutions for Sensitive, Aging Skin This Season
Holiday Skin Stress? KREMOLOGIE Trademark Offers Professional Solutions for Sens …
Professional-grade skincare brand KREMOLOGIE addresses the seasonal skin challenges facing women this holiday season. With formulations rooted in clinical esthetics expertise, the brand provides barrier-strengthening solutions for reactive skin stressed by holiday demands, travel, and harsh winter conditions. The holiday season brings joy, celebration, and unfortunately for many women, significant skin stress. Between November and January, dermatologists and estheticians report increased consultations for dehydration, sensitivity flare-ups, and accelerated aging signs. KREMOLOGIE
Jupiter Landscaping Boosts Home Values in Boynton Beach With High End Landscape Designs
Jupiter Landscaping Boosts Home Values in Boynton Beach With High End Landscape …
Jupiter Landscaping enhances Boynton Beach homes with luxury landscape designs, boosting curb appeal and property value. Boynton Beach, FL - Landscaping experts in Boynton Beach are making a significant impact on home values with their top-tier landscape designs. Specializing in custom landscaping solutions, these professionals offer comprehensive services that enhance curb appeal, create functional outdoor spaces, and increase property value, especially for homeowners seeking Boynton Beach landscaping [https://www.jupiterlandscaping.net/boynton-beach-fl]. "We believe that landscaping
Naples Comfort Systems Delivers Emergency AC Installation Solutions to Protect Golden Gate Families During Extreme Heat
Naples Comfort Systems Delivers Emergency AC Installation Solutions to Protect G …
Naples Comfort Systems provides fast emergency AC installation to keep Golden Gate families safe and cool during extreme heat. Naples, FL - In response to the sweltering temperatures affecting Golden Gate and surrounding areas, Naples Comfort Systems is offering AC Installation Golden Gate FL [https://stahlmanac.com/air-conditioning/golden-gate-fl/] services on an emergency basis to help protect local families from the dangers of extreme heat. As the summer heat intensifies, the company is stepping up
Emergency AC Repair Support Expanded in Golden Gate as Heat Intensifies
Emergency AC Repair Support Expanded in Golden Gate as Heat Intensifies
Emergency AC repair services in Golden Gate expand as rising temperatures increase demand for fast, reliable cooling solutions. Naples, FL - As temperatures in Golden Gate and surrounding areas rise to extreme levels, homeowners and businesses are facing the critical need for reliable air conditioning services. To meet this growing demand, Naples Comfort Systems is significantly boosting its emergency AC Repair Golden Gate FL [https://stahlmanac.com/air-conditioning/golden-gate-fl/], ensuring that residents and businesses stay

All 5 Releases


More Releases for Idiopathic

Idiopathic Pulmonary Fibrosis Market Size & Share Analysis
The new report published by The Business Research Company, titled Idiopathic Pulmonary Fibrosis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends. As per the report, the idiopathic pulmonary fibrosis market size has grown strongly in recent years. It will grow from $3.89
Charting New Frontiers: Idiopathic Gastroparesis Drugs Market Dynamics
The Idiopathic Gastroparesis Drugs Market 𝐑𝐞𝐩𝐨𝐫𝐭 dissects the complex fragments of the Market in an easy-to-read manner. This report covers drivers, restraints, challenges, and threats in the Idiopathic Gastroparesis Drugs Market to understand the overall scope of the Market in a detailed yet concise manner. Additionally, the Market report covers the top-winning strategies implemented by major industry players and technological advancements that steer the growth of the Market. 𝐂𝐥𝐚𝐢𝐦 𝐲𝐨𝐮𝐫 𝐂𝐨𝐩𝐲
Chronic Idiopathic Myelofibrosis Market 2022 | Detailed Report
The Chronic Idiopathic Myelofibrosis report understands the current and future competitive scenario across types, countries, and applications.It provides accurate, up-to-date analysis of markets and companies.The report use reliable information and analysis to gain a deeper understanding of the current factors impacting the industry. The Chronic Idiopathic Myelofibrosis report provides exact and accurate data that helps companies of all sizes to make timely decisions. Furthermore, the report provides robust solutions to customers,
Idiopathic Membranous Nephropathy Treatment Market to Witness Significant Growth …
Idiopathic membranous nephropathy a glomerular disease usually of abrupt onset and associated with the nephrotic syndrome. Membranous nephropathy occurs when the small blood vessels in the kidney (glomeruli), which filter wastes from the blood, become damaged and thickened. As a result, proteins leak from the damaged blood vessels into the urine (proteinuria). R&D in idiopathic membranous nephropathy is expected to aid in growth of the idiopathic membranous nephropathy treatment market. In
Global Idiopathic Scoliosis Treatment Market Size by Type (Infantile Idiopathic, …
Global Idiopathic Scoliosis Treatment‎‎‎‎‎‎‎ Market Research report provides vital information related to the overall market and forecast from 2019 to 2026. This report includes the in-depth analysis of market size, share, growth, trends and regional demand and top layers the Idiopathic Scoliosis Treatment‎‎‎‎‎‎‎ Market. The major players dominating the market are focused upon throughout the by analyzing their revenue, their business summary, product segmentation along with the latest developments. Get Sample
Chronic Idiopathic Constipation Market Research Report 2024
Constipation can be defined as reduced stool frequency or difficulty in passing stool. The frequency may be reduced to less than three times a week. Reduced or difficult stool passage includes hard lumpy stools, incomplete bowel movements, straining, incomplete evacuation, and need for manual removal of stool. Chronic idiopathic constipation (CIC) can be defined as more chronic or severe continuation of these above symptoms. Many times the cause of constipation